Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
2.610
+0.010 (0.38%)
Aug 11, 2026, 3:39 PM EDT - Market open

Cellectar Biosciences Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-22.37-22.98-51.78-38.96-28.81-24.13
Net Income
-20.84-21.79-44.58-42.77-31.79-24.12
Earnings Per Share
-6.66-8.35-41.89-104.99-135.30-130.50
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
8.3513.223.299.5619.8735.7
Total Debt
1.530.410.490.550.60.3
Net Cash (Debt)
6.8212.7922.799.0119.2635.4
Net Cash Growth
-49.23%-43.91%152.94%-53.22%-45.59%-37.61%
Net Cash Per Share
2.084.9018.4122.1281.90191.31

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-18.58-23.12-47.58-32.38-25.22-22.57
Capital Expenditures
-0.01-0.01-0.1-0.86-0.23-0.14
Free Cash Flow
-18.59-23.12-47.69-33.24-25.45-22.71
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.